Peanut Allergy Treatment Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

What Is the Forecasted Market Size and Growth Rate for the Peanut Allergy Treatment Market?
The market size for treating peanut allergies has expanded swiftly over recent years. The industry is predicted to rise from $0.45 billion in 2024 to $0.51 billion in 2025, with a compound annual growth rate (CAGR) of 11.4%. Historical growth can be traced back to surging prevalence rates, breakthroughs in diagnostic testing, heightened public cognizance and apprehension, the formulation of preemptive treatment strategies, and official consent for peanut allergy therapies.

Anticipated to expand significantly in the coming years, the peanut allergy treatment market size is projected to reach $0.77 billion by 2029, with an 11.1% compound annual growth rate (CAGR). Factors such as the persistent surge in allergy prevalence, the widening scope of personalized medicine, the emergence of groundbreaking immunotherapy interventions, growth in both public and private funding, and the broadening of telemedicine services contribute to the predicted growth for the forecast period. Key trends for the forecast period entail an augmenting acceptance of immunotherapy, progress in biologic therapies, incorporation of probiotic-focused treatments, technological advancements in administering systems, personalized medicinal strategies, along with regulatory endorsements and support.

What Factors Are Fueling Growth in the Peanut Allergy Treatment Market?
The growth of the peanut allergy treatment market is predicted to be fueled by investments in the research and development of allergy remedies. The term research and development (R&D) investments implies the allocation of financial resources by companies, institutions, or governments for activities focused on innovation, product enhancement, and technological progress. Such investment is fundamental for the evolution of peanut allergy treatments, facilitating the development of innovative immunotherapies and desensitization methods designed to decrease allergic reactions and enhance life quality for individuals suffering from peanut allergies. For example, in January 2024, the Victorian Government declared a strategic investment of $12 million in Aravax, a clinical-stage biotechnology firm based in Australia, to make significant progress in the global peanut allergy treatment. This investment is a part of a larger $66 million round intended to advance Aravax's ground-breaking immunotherapy, PVX108. This project has received Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia's Therapeutic Goods Administration (TGA), emphasizing its probable global public health impact. Hence, the investment in research and development of allergy treatments is propelling the growth of the peanut allergy treatment market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

Which Businesses Are at the Forefront of Peanut Allergy Treatment Market Development?
Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd., Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

What Are the Latest Innovations in the Peanut Allergy Treatment Market?
Principal firms in the peanut allergy treatment market, like Novartis Pharmaceuticals Corporation, are investing in the creation of biologic therapies like anti-IgE monoclonal antibodies. These strategies are geared towards offering more specific and efficient treatment options for managing peanut allergies, thus enhancing patient results and life quality. Anti-IgE monoclonal antibodies serve as a therapeutic mechanism meant to neutralize immunoglobulin E (IgE) antibodies within a person's body. For example, in February 2024, the Switzerland-based Novartis Pharmaceuticals Corporation gained approval for Xolair (omalizumab) from the Food and Drug Administration (FDA). The drug is formulated to curb allergic reactions, inclusive of anaphylaxis, in those aged one year and above suffering from IgE-related food allergies. This greenlight was informed by data gathered from the NIH-backed Phase III OUtMATCH study, which presented notable progress in food allergy tolerance in patients on Xolair contrasted with those on a placebo.

How Is the Peanut Allergy Treatment Market Segmented?
The peanut allergy treatment market covered in this report is segmented -

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:
1) By Antihistamines: Oral Antihistamines, Topical Antihistamines
2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)
3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers
4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Where Is the Peanut Allergy Treatment Market Growth Most Prominent?
North America was the largest region in the peanut allergy treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Peanut Allergy Treatment Global Market Report?

- Market Size Analysis: Analyze the Peanut Allergy Treatment Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Peanut Allergy Treatment Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Peanut Allergy Treatment Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Peanut Allergy Treatment Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15888

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.